Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer

Sanjit K Roy, Rakesh K Srivastava, Sharmila Shankar

Abstract

Background: Mammalian forkhead members of the class O (FOXO) transcription factors, including FOXO1, FOXO3a, and FOXO4, are implicated in the regulation of several biological processes, including the stress resistance, metabolism, cell cycle, apoptosis and DNA repair. The objectives of this study were to examine the molecular mechanisms by which FOXO transcription factors induced cell cycle arrest and apoptosis and enhanced anti-proliferative effects of sulforaphane (SFN, an active compound in cruciferous vegetables) in pancreatic cancer cells.

Results: Our data demonstrated that SFN inhibited cell proliferation and colony formation, and induced apoptosis through caspase-3 activation in pancreatic cancer cells. The inhibition of PI3K/AKT and MEK/ERK pathways activated FOXO transcription factors. SFN inhibited phosphorylation of AKT and ERK, and activated FOXO transcription factors, leading to cell cycle arrest and apoptosis. Phosphorylation deficient mutants of FOXO proteins enhanced FOXO transcriptional activity, and further enhanced SFN-induced FOXO activity and apoptosis. SFN induced the expression of p21/CIP1 and p27/KIP1, and inhibited the expression of cyclin D1.

Conclusion: These data suggest that inhibition of PI3K/AKT and ERK pathways acts together to activate FOXO transcription factor and enhances SFN-induced FOXO transcriptional activity, leading to cell cycle arrest and apoptosis.

Background

Cancer of the pancreas is the fourth leading cause of cancer death in the United States. This year approximately 32,000 Americans will die from cancer of the pancreas. With an overall 5-year survival rate of 3% [1], pancreatic cancer has one of the poorest prognoses among all cancers [2]. Only 20% of pancreatic cancer patients are eligible for surgical resection, which currently remains the only potentially curative therapy [3]. Unfortunately, many cancers of the pancreas are not resectable at the time of diagnosis. There are limited treatment options available for this disease because chemo- and radio-therapies are largely ineffective, and metastatic disease frequently redevelops even after surgery [1,2]. Therefore, developing effective strategies to prevent pancreatic neoplasms are of paramount importance.

Sulforaphane (SFN), a constituent of cruciferous vegetables, is a naturally occurring isothiocyanate with promising chemopreventive activity [4]. Epidemiological studies have shown that people who eat cruciferous vegetables have reduced incidence of breast and prostate cancer. SFN possesses anti-oxidant, anti-proliferative and anti-carcinogenic properties [5-7]. SFN is effective in preventing chemically induced breast [8,9], stomach [5] and colon [10] cancers in rats. We and others have shown that SFN inhibited the growth of prostate, breast, oral and squamous carcinoma xenografts [11-15]. SFN enhanced radiosensitivity of tumor cells in vitro and in vivo [16]. Furthermore, a pharmacokinetic study has demonstrated that it is rapidly absorbed and 82% bioavailable [17]. SFN induces a phase 2 enzyme, thereby neutralizing carcinogens before they...
can damage DNA [18,19]. SFN inhibits benzo[a]pyreneDNA and 1,6-dinitropyrene-DNA adducts formation [20-23], and downregulates PI3K/AKT [24,25] and NFκB [12,26,27] pathways. We have recently demonstrated that SFN induces death receptors (DR4 and DR5) and proapoptotic members of Bcl-2 family, inhibits antiapoptotic Bcl-2 proteins, activates caspase(s), and enhances apoptosis-inducing potential of TRAIL in vitro [12]. In vivo, SFN inhibits growth of PC-3 cells orthotopically implanted in nude mice by inducing apoptosis and inhibiting tumor cell proliferation, metastasis and angiogenesis [12]. These studies strongly suggest that SFN can be developed as a cancer preventive agent.

PTEN (phosphatase and tensin homolog deleted on chromosome 10, also called MMAC1 or TEP1) is a tumor suppressor gene [28-30], which is frequently deleted or mutated in a wide range of human cancers, including glioblastoma [31], melanoma [32], and prostate [33], breast [34], and endometrial cancers [35]. While point mutations in PTEN rarely occur in pancreatic cancer [36,37], functional inactivation of PTEN through promoter methylation [38], loss of protein expression [39], reduction of mRNA levels [40], or loss of heterozygocity (LOH) of linked markers [37,41] occur with high frequency. Phosphatidylinositol 3,4,5-trisphosphate (PIP3) is a substrate of PTEN [42-44]. AKT is a serine-threonine protein kinase regulated by PIP3 that is implicated in survival signaling in a wide a variety of cells, including fibroblastic, epithelial, and neuronal cells [45]. PTEN increases sensitivity to cell death in response to several apoptotic stimuli by negatively regulating the PI3K/AKT pathway [43]. In addition to its role in regulating the PI3K/AKT cell survival pathway, PTEN also inhibits growth factor-induced Shc phosphorylation and suppresses the MAP kinase signaling pathway [46], suggesting that PTEN has roles in independent of PI3K/AKT signaling pathway. Hyperactivation of AKT is associated with resistance to apoptosis, increased cell growth, cell proliferation, metastasis, angiogenesis, and cellular energy metabolism [45,47-54]. Overexpression of AKT has been reported in a variety of human cancers, including pancreatic cancer, and cells expressing elevated levels of AKT are less sensitive to apoptosis stimuli [38,55-57]. Antagonizing PI3K activity negatively regulates AKT activity. Once activated, however, AKT exerts antiapoptotic effects through phosphorylation of substrates such as Bad [58,59] and caspase-9 [60] that directly regulate the apoptotic machinery, or human telomerase reverse transcriptase subunit [61], forkhead transcription family members [62,63] and IB kinases [64] that indirectly inhibit apoptosis [65]. Studies in pancreatic cancer cell lines have demonstrated that PI3K is required for growth and survival of tumor cells [66-68]. Furthermore, amplification or activation of AKT2 occurs in up to 60% of pancreatic cancer [39,69-71], supporting the participation of an activated PI3K-AKT axis in this disease.

FOXO subfamily of forkhead transcription factors include FOXO1a/FKHR, FOXO3a/FKHRL1, and FOXO4/AFX [72-75]. The PI3K pathway, via activation of its downstream kinase AKT, phosphorylates each of the FOXO proteins [62,76,77]. These phosphorylations result in impairment of DNA binding ability and increased binding affinity for the 14-3-3 protein [62,77]. Newly formed 14-3-3-FOXO complexes are then exported from the nucleus [78], thereby inhibiting FOXO-dependent transcription. Inhibition of the PI3K pathway leads to dephosphorylation and nuclear translocation of active FKHRL1, FKHR, and AFX; which induce cells cycle arrest and apoptosis [79]. Conversely, loss of PTEN activity results in increased AKT activity leading to inhibition of FOXO protein activity through phosphorylation and cytoplasmic sequestration. In addition, the data demonstrate that FOXO transcriptional activity controls cellular proliferation and apoptosis downstream of PTEN [80,81]. FOXO regulates cell cycle and apoptotic genes such as cyclin-dependent kinase inhibitor (CKI) p27KIP1 [78,80,82,83], Bim [84,85], Fas ligand [62], and Bcl-6 [86]. Consequently, activation of the PI3K pathway serves to repress FOXO-mediated growth arrest and apoptosis. However, regulation of FOXO target genes is multifactorial, and therefore other transcription factors and post-translation regulatory events will influence the final level of protein expression. Interestingly, overexpression of AKT, and inactivation and loss of PTEN are frequently observed in pancreatic cancer [39,66-71], indicating a potential role for FOXOs in modulating both cell cycle and apoptosis during tumorigenesis and treatment. Together, these results indicate that FOXO proteins are important downstream effectors of PTEN tumor suppressive activity; however, their molecular targets and mechanisms of action in pancreatic cancer are not well understood.

The Ras proteins are small (21 kDa) GTP-binding, membrane-associated proteins [87]. The Ras proteins transduce signals from ligand-activated tyrosine kinase receptors to downstream effectors [88]. Activating mutations can impair GTP hydrolysis and lead to constitutively activated Ras that impacts the cellular phenotype [89]. Oncogenic Ras can lead to cellular transformation [90], presumably by perturbing its signal transduction pathways. Ras regulates multiple signaling pathways [91]. Three major groups of MAP kinases are found in mammalian cells: extracellular signal-regulated protein kinase (ERK) [92], p38 MAP kinase [93], and c-Jun N-terminal kinase (JNK) [94-96]. MAP kinases regulate many cellular activities, which range from gene expression to mitosis, movement, metabolism, and apoptosis.
These MAP kinases are activated by the dual phosphor-
ylations of neighboring threonine and tyrosine residues
in response to various extracellular stimuli [97,98]. Spec-
ifically, p38 and JNK have been implicated in stress-
responsive signaling leading to the initiation of adaptive
events such as gene expression, differentiation, metabo-
limism, and apoptosis [94,95,99]. ERKs are often activated
by growth signals, such as epidermal growth factor
(EGF) or platelet-derived growth factor [100]. We have
recently demonstrated that inhibition of PI3K/AKT and
MEK/ERK pathways act synergistically to regulate anti-
angiogenic effects of EGCG and SFN through activation
of FOXO transcription factors [24,101].

Furthermore, FOXO transcription factors play a cru-
ical role in the regulation of tissue homeostasis in
organs such as the pancreas, and complex diseases such
as diabetes and cancer. Unfortunately, the intracellular
mechanisms by which SFN inhibits growth and induces
apoptosis in pancreatic cancer cells through regulation
of FOXO transcription factors have never been exam-
ined. The objectives of our study were to examine the
molecular mechanisms by which FOXO transcription
factors induce cell cycle arrest and apoptosis and
enhances the anti-proliferative effects of SFN in pan-
creatic cancer cells. Our results demonstrate that inhibi-
tion of PI3K/AKT and ERK pathways activates FOXO
transcription factors. SFN inhibited phosphorylation of
AKT and ERK, and dephosphorylated FOXO transcrip-
tion factors, leading to cell cycle arrest and apoptosis.
Phosphorylation deficient mutants of FOXO proteins
enhanced FOXO transcriptional activity, and further
enhanced SFN-induced FOXO activity.

Results
Sulforaphane (SFN) inhibits cell growth in human
pancreatic cancer cells
We first examined the effects of SFN on cell prolifera-
tion in four pancreatic cancer cell lines by XTT assay.
We have selected four pancreatic cancer cell lines (MIA
PaCa-2, AsPC-1, PANC-1 and Hs766T) because they
have been derived from different pathological stages and
may thus respond differently to SFN [102,103]. MIA
PaCa-2 harbors a point mutation on Kras gene resulting
in amino acid substitution from the wild-type glycine
to a valine at codon 12. AsPC-1 and PANC-1 harbor a
point mutation on Kras gene resulting in amino acid
substitution from glycine to aspartate. Hs766T cell line
does not possess a point mutation in codon 12 of the
Kras gene. SFN inhibited cell viability in a dose depen-
dent manner (Fig. 1). PANC-1 and MIA PaCa-2 cell
lines were most sensitive, AsPC-1 cell line was moder-
ately sensitive, and Hs766T cell line was least sensitive.
These data suggest that SFN can be a viable agent for
inhibiting pancreatic cancer cell proliferation.

Sulforaphane inhibits colony formation in human
pancreatic cancer cells
We next examined the effects of SFN on colony forma-
tion (a characteristic of cancer) on four pancreatic cancer
cell lines by soft agar assay. SFN inhibited colony
formation in a dose dependent manner (Fig. 2). Colonies
formed by PANC-1 and MIA PaCa-2 cells were most
sensitive, AsPC-1 cell line was moderately sensitive, and
Hs 766T cell line was least sensitive. These data suggest
that SFN can be used as a potent chemopreventive
agent for pancreatic cancer.

Sulforaphane induces caspase-3 activation in human
pancreatic cancer cell
Most chemopreventive agents induce apoptosis through
mitochondrial pathway, which activates caspase-3 [104].
We therefore examined whether SFN-induced apoptosis
through caspase-3 activation in pancreatic cancer cell lines
(Fig. 3). SFN induced caspase-3 activity in PANC-1, MIA
PaCa-2, Hs 766T and AsPC-1 cells. However, a relatively
high dose of SFN was required to activate caspase-3 in Hs
766T cells compared to other pancreatic cancer cell lines.
These data suggest that SFN induced apoptosis through
caspase-3 activation and may engage the mitochondria.

Regulation and function of PI3K/AKT and MAP kinase
pathways by sulforaphane
In most cancer cells, AKT is constitutively active and
enhances cell proliferation [105]. In order to understand
a relationship between PTEN and AKT in SFN-induced
apoptosis, we measured the expression of PTEN and
phosphorylation status of AKT in cells treated with SFN
(Fig. 4A). SFN induces PTEN expression and inhibits
AKT phosphorylation in pancreatic cancer PANC-1
cells. By comparison, SFN has no effect on total AKT
expression. These data suggest that SFN inhibits cell
proliferation by regulating PI3K/AKT pathway.

Ras/Raf/MAP kinase pathway regulates many cellular
activities, which range from gene expression to mitosis,
movement, metabolism, and apoptosis [94,106-109]. We
therefore examined the effects of SFN on the expression
of Ras, and activation of ERK, JNK and p38 MAP
kinases. SFN inhibited Ras expression in PANC-1 cells
(Fig. 4A). Treatment of PANC-1 cells with SFN caused
a decrease in ERK phosphorylation, and an increase in
JNK phosphorylation. SFN has no significant effect on
p38 MAP kinase activity in PANC-1 cells. These data
suggest that SFN inhibits growth and induces apoptosis
through regulation of Ras/Raf/MAP kinase pathway.

We next examined whether SFN induces apoptosis
through PI3K/AKT pathway (Fig. 4B). Pancreatic cancer
cells were transfected with empty vector, wild type
PTEN, dominant negative AKT (DN-AKT), and apopto-
sis was measured. Overexpression of wild type PTEN or
Figure 1 Effect of sulforaphane (SFN) on viability of pancreatic cancer cells. Pancreatic cancer (PANC-1, MIA PaCa-2, Hs766T and AsPC-1) cells were treated with SFN (0–30 μM) for 48 h. Cell viability was measured by XTT assay. Data represent the mean ± S.D. * = significantly different from respective controls, P < 0.05.

Figure 2 Effect of sulforaphane (SFN) on colony formation. Pancreatic cancer (PANC-1, MIA PaCa-2, Hs766T and AsPC-1) cells were treated with SFN (0–20 μM), and number of colonies were counted. Data represent the mean ± S.D. * = significantly different from respective controls, P < 0.05.
DN-AKT induced apoptosis in AsPC-1 and PANC-1 cells. Treatment of transfected cells with SFN further enhanced apoptosis. These data suggest that inhibition of PI3K/AKT pathway enhances SFN-induced apoptosis in pancreatic cancer cells.

We next examined whether inhibition of MEK/ERK pathway enhances SFN-induced apoptosis in pancreatic cancer cells. MEK1/2 inhibitor (PD98059) induced apoptosis in PANC-1 and AsPC-1 cells (Fig. 4C). PD98059 enhanced SFN-induced apoptosis. Overall, these data suggest that inhibition of PI3K/AKT and MEK/ERK pathways enhanced SFN-induced apoptosis.

Sulforaphane induces p21^{WAF1/CIP1}, and p27^{KIP1} and inhibits cyclin D1

PI3K/AKT signaling pathway may be involved in the control of the cell cycle progression most likely through mechanisms involving the activation of FOXO transcription factors [82]. We next examined the effects of SFN on cell cycle regulatory genes. SFN induced the expression of cell cycle inhibitors p21^{WAF1/CIP1} and p27^{KIP1}, and inhibited the expression of cyclin D1 in PANC-1 cells (Fig. 5). These data suggest that SFN causes growth arrest by regulating expression of cell cycle genes.

**Overexpression of FOXO transcription factors inhibits cell viability and enhances FOXO transcriptional activity in pancreatic cancer cells**

In order to examine whether FOXO transcription factors affect the ability of SFN to inhibit cell viability, pancreatic cancer cells were transfected with FOXO1, FOXO3a or FOXO4 (Fig. 6A and 6B). FOXO expression plasmids and FOXO-luciferase construct (pGL3-6X DBE) have previously been described [101]. Overexpression of FOXO1, FOXO3a, and FOXO4 inhibited cell viability in PANC-1 and AsPC-1 cells. The inhibitory effects of SFN on cell viability were further enhanced when pancreatic cancer cells were transfected with FOXO1, FOXO3a, and FOXO4. These data suggest that FOXO transcription factors can enhance the antiproliferative effects of SFN.

We next examined whether SFN induces transcriptional activation of FOXO in the presence or absence phosphorylation deficient triple mutants of FOXO proteins (FOXO1-TM, FOXO3a-TM, or FOXO4-TM). PANC-1 and AsPC-1 cells were transfected with wild type FOXO promoter linked to a luciferase reporter gene in the presence or absence of plasmids expressing FOXO1-TM, FOXO3a-TM, or FOXO4-TM (Fig. 6C).
and 6D). After transfection, cells were treated with SFN for 24 h, and luciferase activity was measured. Transfection of cells with plasmids expressing FOXO1-TM, FOXO3a-TM, or FOXO4-TM induced FOXO transcriptional activity compared with the empty vector (control). SFN-induced FOXO transcriptional activity was further enhanced in the presence of FOXO1-TM, FOXO3a-TM, and FOXO4-TM. These data indicate that FOXO transcription factor may play a major role in mediating biological effects of SFN in pancreatic cancer cells.

**Inhibition of PI3K/AKT and MEK/ERK pathways synergistically/additively induces FOXO transcriptional activity and apoptosis in the presence or absence of sulforaphane**

Since inhibition of PI3K/AKT and MEK/ERK pathways induce apoptosis in pancreatic cancer cells, we sought to examine whether these pathways act together to regulate SFN-induced apoptosis. AKT inhibitor (AKT Inh-IV) and MEK1/2 inhibitor (PD98059) synergistically/additively induced apoptosis in PANC-1 and AsPC-1 cells (Fig. 7A and 7B). AKT inhibitor and PD98059 alone enhanced SFN-induced apoptosis. Interestingly, the combination of AKT inhibitor and PD98059 with SFN induced more apoptosis than AKT inhibitor plus SFN or PD98059 plus SFN. These data suggest that inhibition of PI3K/AKT and MEK/ERK pathways act synergistically/additively to regulate apoptosis in the absence or presence of SFN.

Since inhibition of PI3K/AKT and MEK/ERK pathways synergistically/additively induces apoptosis in pancreatic cancer cells, we sought to examine whether inhibition of these two pathways act together to regulate FOXO activity. AKT inhibitor (AKT Inh-IV) and
MEK1/2 inhibitor (PD98059) synergistically induced FOXO transcriptional activity in AsPC-1 and PANC-1 cells (Fig. 7C and 7D). AKT inhibitor or PD98059 enhanced SFN-induced FOXO transcriptional activity. Interestingly, the combination of AKT Inh-IV and PD98059 with SFN induced greater FOXO transcriptional activity than AKT Inh-IV plus SFN or PD98059 plus SFN. These data suggest that inhibition of PI3K/AKT and MEK/ERK pathways acts synergistically/additively to regulate FOXO transcriptional activity in the absence or presence of SFN.

Discussion

Our study demonstrates, for the first time, that cancer preventive effects of SFN are regulated through activation of FOXO transcription factors. Specifically, we have demonstrated that (i) SFN induces apoptosis through caspase-3 activation, and causes growth arrest through induction of p21 and p27 and inhibition of cyclin D1; (ii) SFN induces apoptosis through inhibition of both PI3K/AKT and MEK/ERK pathways, and activation of FOXO transcription factors; (iii) inhibition of PI3K/AKT and MEK/ERK pathways acts together to enhance the activation of FOXO transcription factors; and (iv) phosphorylation deficient mutants of FOXO proteins further enhance SFN-induced FOXO activity and apoptosis. Our data are in agreement with others who demonstrated the anticancer activity of SFN in pancreatic cancer [110-112].
FOXO transcription factors play a crucial role in the regulation of tissue homeostasis in organs such as the pancreas and the ovaries and complex diseases such as diabetes and cancer [113-117]. FOXO transcription factors are emerging as critical transcriptional integrators among pathways regulating differentiation, proliferation, survival, and angiogenesis [118-121]. FOXO transcription factors regulate angiogenesis and postnatal neovascularization by regulation angiopoietin 2 (Ang2) and eNOS [121]. Gene expression profiling showed that FOXO1 and FOXO3a specifically regulate a nonredundant but overlapping set of angiogenesis- and vascular remodeling-related genes [121]. The FOXO1-deficient mice died around embryonic day 11 because of defects in the branchial arches and remarkably impaired vascular development of embryos and yolk sacs [118]. We have recently demonstrated that inhibition of the MEK/ERK and PI3K/AKT pathways synergistically induced FOXO transcriptional activity and inhibited angiogenesis (cell migration and capillary tube formation); these events were further enhanced in the presence of SFN [24]. Phosphorylation deficient mutants of FOXO enhanced antiangiogenic effects of SFN by activating the FOXO transcription factor. These studies suggest that activation of FOXO transcription factor by SFN could be an important physiological process to inhibit angiogenesis which may ultimately control tumor growth.

Activation of Kras has been shown to activate both PI3K/AKT and MAPK pathways [24,101,122-124]. Oxidative stress and activation of the JNK pathway induce the nucleocytoplasmic translocation of the pancreatic transcription factor Pdx-1, which leads to pancreatic β-cell dysfunction [125,126]. Furthermore, FOXO1/FKHR plays a role as a mediator between the JNK pathway and Pdx-1 [127]. Under oxidative stress conditions, FOXO1 changed its intracellular localization from the cytoplasm to the nucleus in the pancreatic β-cell line HIT-T15. The overexpression of JNK also induced the nuclear localization of FOXO1, but in contrast, suppression of JNK reduced the oxidative stress-induced
nuclear localization of FOXO1, suggesting the involvement of the JNK pathway in FOXO1 translocation. In addition, oxidative stress or activation of the JNK pathway decreased the activity of AKT in HIT cells, leading to the decreased phosphorylation of FOXO1 following nuclear localization. Furthermore, adenovirus-mediated FOXO1 overexpression reduced the nuclear expression of Pdx-1, whereas repression of FOXO1 by FOXO1-specific small interfering RNA retained the nuclear expression of Pdx-1 under oxidative stress conditions. Activation of ERK has been shown to phosphorylate FOXO proteins, resulting in nuclear exclusion and transcriptional repression. In addition to ERK, direct phosphorylation of FOXO by AKT results in cytoplasmic retention and inactivation, inhibiting the expression of FOXO-regulated genes, which control the cell cycle, cell death, cell metabolism and oxidative stress [82,128,129]. Taken together, these studies demonstrate that dephosphorylation and activation of FOXO by inhibition of PI3K/AKT and MEK/ERK pathways has significant implication for pancreatic cancer treatment and prevention, where Kras is activated in about 90% patients.

In addition to phosphorylation, the acetylation/deacetylation of FOXO can be regulated by p300, Cbp (CREB-binding protein) and Pcaf (p300/CBP-associated factors) in response to oxidative stress or DNA binding, followed by deacetylation by class I and II histone deacetylases [130-132], including Sirt1, the NAD+ dependent deacetylase encoded by the ortholog of yeast longevity gene Sir2 [133]. Therefore, further studies are needed to examine the consequences of acetylation/deacetylation of FOXO transcription factors on anti-proliferative and anti-angiogenic effects of SFN.

In conclusion, we have demonstrated that SFN induces cell cycle arrest and apoptosis through regulation of FOXO transcription factors. Pharmacological and genetic inhibitions of PI3K/AKT and MEK/ERK pathways have synergistic effects on the activation of FOXO transcription factors through dephosphorylation and nuclear retention. Thus, SFN appears to be as an attractive agent for pancreatic cancer prevention and treatment.

**Methods**

**Reagents**

Antibodies against PTEN, phospho-AKT, AKT, phospho-ERK, ERK, phospho-p38, p38, p21/CIP1, p27/KIP1, cyclin D1, and β-actin were purchased from Cell Signaling Technology, Inc. (Danvers, MA). Enhanced chemiluminescence (ECL) Western blot detection reagents were from Amersham Life Sciences Inc. (Arlington Heights, IL). Terminal Deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) assay kit was purchased from EMD Biosciences/Calbiochem (San Diego, CA). Sulforaphane was purchased from LKT Laboratories, Inc. (St. Paul, MN). Kits for Terminal Deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) and caspase-3 assays were purchased from EMD Biosciences/Calbiochem (San Diego, CA).

**Cell Culture**

PANC-1, MIA PaCa-2, AsPC-1 and Hs 766T cells were obtained from the American Type Culture Collection (Manassas, VA) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic (Invitrogen) at 37°C in a humidified atmosphere of 95% air and 5% CO₂.

**Western Blot Analysis**

Western blots were performed as we described earlier [134,135]. In brief, cells were lysed in RIPA buffer containing 1 × protease inhibitor cocktail, and protein concentrations were determined using the Bradford assay (Bio-Rad, Philadelphia, PA). Proteins were separated by 12.5% SDS/PAGE and transferred to membranes (Millipore, Bedford, MA) in a Tris (20 mM), glycine (150 mM) and methanol (20%) buffer at 55 V for 4 h at 4°C. After blocking in 5% nonfat dry milk in TBS, the membranes were incubated with primary antibodies at 1:1,000 dilution in TBS overnight at 4°C, washed three times with TBS-Tween 20, and then incubated with secondary antibodies conjugated with horseradish peroxidase at 1:5,000 dilution in TBS for 1 hour at room temperature. Membranes were washed again in TBS-Tween 20 for three times at room temperature. Protein bands were visualized on X-ray film using an enhanced chemiluminescence detection system.

**Caspase-3 Assay**

Cells (3 × 10⁴ per well) were seeded in a 96-well plate with 200 μl culture medium. Approximately 16 h later, cells were treated with various doses of SFN to induce apoptosis. Caspase-3 activity was measured by a fluorometer as per manufacturer’s instructions (EMD Biosciences).

**Statistical Analysis**

The mean and SD were calculated for each experimental group. Differences between groups were analyzed by one or two way ANOVA, followed by Bonferroni’s multiple comparison tests using PRISM statistical analysis software (GrafPad Software, Inc., San Diego, CA). Significant differences among groups were calculated at P < 0.05.

**List of abbreviations used**

ANOVA: Analysis of Variance; PTEN: Phosphatase and Tensin Homolog; Deleted on Chromosome 10; RIPA: Radio-Immunoprecipitation Assay; SDS-PAGE: Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis; SFN: Sulforaphane; TBS: Tris Buffer Saline.
Acknowledgements
We thank our lab members for critical reading of the manuscript. We also thank Dr. Noboru Motoyama (National Institute for Longevity Sciences, Obu, Aichi, Japan) and Dr. Tatsuo Furuyama (Sonoda Women’s University, Amagasaki, Hyogo, Japan) for providing FOXY expression plasmids and FOXO-luciferase construct (pCGL-6X DBE), respectively. This work was supported in part by the grants from the National Institutes of Health (R01CA125262 and R01CA114469).

Author details
1Department of Pharmacology, Toxicology and Therapeutics, and Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA. 2Department of Pathology and Laboratory Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160, USA.

Authors’ contributions
SKR and SS performed the experiments. SS and RKS designed and wrote the manuscript. All the authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 22 June 2010 Accepted: 19 July 2010 Published: 19 July 2010

References
1. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 1992, 326:455-465.
2. Magee CJ, Ghanem P, Neoptolemos JP: Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol 2002, 16:435-455.
3. Yeo TP, Huban RH, Leach SD, Wintz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, et al: Pancreatic cancer, Curr Probl Cancer 2002, 26:176-275.
4. Fahey JW, Talalay P: Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxification enzymes. Food Chem Toxicol 1999, 37:973-979.
5. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Roy et al: Sulforaphane-mediated induction of a phase 2 detoxifying enzyme NADPH quinone reductase and apoptosis in human lymphoblastoid cells. Acta Biochim Pol 2004, 51:711-721.
6. Becker JM, Gardner G, Lappin G, Langouet S, Bao Y: Sulforaphane and quercetin modulate PHIP-DNA adduct formation in human HepG2 cells and hepatocytes. Carcinogenesis 2003, 24:1903-1911.
7. Peng Y, Chen JS, Genner PA, Fahey JW, Jacobson LP, Stephens KN, Ye L, Goodyer JL, Wang JB, Wu Y, et al: Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People’s Republic of China. Cancer Epidemiol Biomarkers Prev 2005, 14:2605-2613.
8. Conaway CC, Wang CK, Pittman B, Yang YM, Schwartz JE, Tian D, McIntee EJ, Hecht SS, Chun FL: Phenylenediisothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. Cancer Res 2005, 65:8548-8557.
9. Singletary K, MacDonald C: Inhibition of benzo[a]pyrene- and 1,6-dinitropyrene-DNA adduct formation in human mammary epithelial cells bydibenzoylmethane and sulforaphane. Cancer Lett 2000, 153:47-54.
10. Davis R, Singh KP, Kurzrock R, Shankar S: Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep 2009, 22:1473-1478.
11. Jakubikova J, Sedlak J, Mithen R, Bao Y: Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem Pharmacol 2005, 69:1543-1552.
12. Cheung KL, Kong AN: Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention, AAPS J 2010, 12:87-97.
13. Choi S, Lew KL, Xiao H, Herman-Antosiewicz A, Xiao D, Brown CK, Singh SV: D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1. Carcinogenesis 2007, 28:151-162.
14. Li J, Yen C, Liaw D, Podosypina K, Bosc S, Wang SI, Puc J, Millaire C, Rodgers L, McCombie R, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
15. Cho NP, Han HS, Leem DH, Choi IS, Jung JY, Kim HJ, Moon KS, Choi KH, Soh Y, Kong G, et al: Sulforaphane enhances caspase-dependent apoptosis through inhibition of cyclooxygenase-2 expression in human oral squamous carcinoma cells and nude mouse xenograft model. Oral Oncol 2009, 45:654-660.
16. Yu D, Sekine-Suzuki E, Xue L, Fujimori A, Kubota N, Okayasu R: Chemopreventive agent sulforaphane enhances radiosensitivity in human tumor cells. Int J Cancer 2009, 125:1205-1211.
17. Hanlon N, Coldham N, Gielbert A, Kuhnert N, Sauer MJ, King LJ, Ioannides C: Absolute bioavailability and dose-dependent pharmacokinetic behaviour of dietary doses of the chemopreventive isothiocyanate sulforaphane in rat. Br J Nutr 2008, 99:559-564.
18. Rushmore TH, Kong AH: Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 2002, 3:481-490.
19. Misiewicz I, Skupinska K, Kowalska E, Lubinski J, Kazprzycka-Guttman T: Sulforaphane-mediated induction of a phase 2 detoxifying enzyme NAD(P)H:quinone reductase and apoptosis in human lymphoblastoid cells. Acta Biochim Pol 2004, 51:711-721.
Programmed cell death: alive and well in...

Caldas C, Weinstein CL, Fischer A, Yeo CJ, 2004, 280:687-689.

Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321.

Kang SS, Kwon T, Kwon DY, Do SJ. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999, 274:13085-13090.

Brunet A, Bonni A, Zigmond MJ, Lin MZ, Luo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 99:177-187.

Kops GJ, de Rutter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 1999, 398:630-634.

Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PGDF signalling. Nature 1999, 401:86-90.

Droz ON, Mayo LD, Gautin JA, Pfeiffer SR, Pfeiffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 402:82-85.

Perugini RA, McCabe TD, Vittimberga FJ Jr, Callery MP. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000, 99:33-44.

Shah SA, Potter MW, Hedehian MH, Kim BD, Chari RS, Callery MP. PI3-kinase and Akt pathway induction by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401:82-85.

Perugini RA, McCabe TD, Vittimberga FJ Jr, Callery MP. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000, 99:33-44.

Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3-kinase-AKT pathway induces apoptosis in pancreatic cancer cells in vitro and in vivo. Mol Cancer Ther 2002, 1:989-997.

Cheng QJ, Ruggieri B, Klein WM, Sonoda G, Aitormae DA, Watson DK, Testa JR. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Mol Ther 1999, 2:177-182.

Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 2005, 30:35-42.

Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Roy et al. Inhibition of the phosphatidylinositol 3-kinase/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res 2002, 62:9209-9217.

Cicenas J, Urban P, Vuarogues V, Labuhn M, Kung W, Wight E, Mayhew M, Eppenberger U, Eppenberger-Castori S. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 2005, 7:R394-401.
1 promoter activity through a conserved insulin response sequence. J Biol Chem 1999, 274:17184-17192.

78. Medema RH, Kops GJ, Boon JJ, Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404:782-787.

79. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000, 20:8969-8982.

80. Dijkers PF, Medema RH, Pals C, Barrenier S, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lamers JW, Koenderman L, Coffer PJ. Forkhead transcription factor FKHRL1 modulates cytokine-dependent transcriptional regulation of p27kip1. Mol Cell Biol 2000, 20:9138-9148.

81. Dijkers PF, Birkenkamp KJ, Lam EW, Thomas NS, Lamers JW, Koenderman L, Coffer PJ. FKHRL1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol 2002, 156:531-542.

82. Cappellini A, Tabellini G, Zanetta M, Bortol MI, Billi AM, Fala F, Cocco L, Martelli AM. The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27kip1 (Kip1) and control of cyclin D1 expression. Leukemia 2003, 17:2157-2167.

83. Burgers GM, Coffer PJ. Cell cycle and death control: long live Forkheads. Trends Biochem Sci 2002, 27:382-386.

84. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003, 162:613-622.

85. Tang TT, Dowbenko D, Jackson A, Toney L, Lewin DA, Dent AL, Lasky LA. The forkhead transcription factorAFX activates apoptosis by induction of the BCL-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000, 10:1201-1204.

86. Davis RJ. Mitogen-activated protein kinases: specific activated protein kinases, ERKs, in preventing heat-induced cell death. Trends Cell Biol 2002, 12:243-250.

87. Robinson MJ, Cobb MH. Signal transduction by the JNK group of MAP kinases. Curr Opin Cell Biol 1999, 11:243-244.

88. Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther 2004, 3:1239-1248.

89. Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 2003, 301:215-218.

90. Nakae J, Briggs WH, Kitamura T, Cavanaugh WK, Wright CV, Arden KC, Accili D. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 2002, 32:245-253.

91. Li D, Xie K, Wolff R, Abbруззы J. Pancreatic cancer. Lancet 2004, 363:1049-1057.

92. Srivastava RK. Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol Cell Biol Res Commun 2000, 4:67-75.

93. Han J, Ulevitch RJ. JNK signaling pathway: activation and inactivation. J Biol Chem 1999, 273:17184-17192.

94. Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther 2004, 3:1239-1248.

95. Farooq A, Zhou MM. Structure and regulation of MAPKs. Cell Signal 2004, 16:769-779.

96. Lubinus M, Meier KE, Smith EA, Gause KC, LeRoy EC, Trojanowska M. The p38 signal transduction pathway: activation and inactivation. J Biol Chem 2000, 273:1613-1622.

97. Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 2003, 301:215-218.

98. Dejan E, Taddei A, Randi AM: Foxo and Fos in the regulation of transcriptional endotheral cell differentiation and angiogenesis. Biochem Biophys Acta 2007, 1775:298-312.

99. Chien S, Pressey JG, Barr FG. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol Ther 2002, 1:97-104.

100. Lubinus M, Meier KE, Smith EA, Gause KC, LeRoy EC, Trojanowska M. Inhibition of p38/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor. J Mol Signal 2008, 3:7.

101. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002, 2:897-909.

102. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Acts. Genes Dev 1999, 13:2905-2927.

103. Mielke K, Herdegen T. JNK and p38 stress kinases—degenerative effectors of signal-transduction cascades in the nervous system. Prog Neurobiol 2000, 61:45-60.

104. Srivastava RK. Intracellular mechanisms of TRAIL and its role in cancer therapy. Mol Cell Biol Res Commun 2000, 4:67-75.

105. Camps M, Nichols A, Arkinist S. Dual specificity phosphatases: a gene family for control of MAP kinase function. Faseb J 2000, 14:56-16.

106. Arden KC, Accili D. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 2002, 110:1839-1847.

107. Srivastava RK, Unterman TG, Shankar S. Dual specificity phosphatases: a gene family for control of MAP kinase function. Faseb J 2000, 14:56-16.

108. Arden KC, Accili D. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest 2002, 110:1839-1847.

109. Srivastava RK, Unterman TG, Shankar S. Dual specificity phosphatases: a gene family for control of MAP kinase function. Faseb J 2000, 14:56-16.
126. Kaneto H, Kawamori D, Nakatani Y, Gorogawa S, Matsuoka TA: Oxidative stress and the JNK pathway as a potential therapeutic target for diabetes. Drug News Perspect 2004, 17:447-453.

127. Kawamori D, Kaneto H, Nakatani Y, Matsuoka TA, Matsuhisa M, Hori M, Yamasaki Y: The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J Biol Chem 2006, 281:1091-1098.

128. Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffier P, Burgering BM, Medema RH: The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 2002, 168:5024-5031.

129. Uddin S, Hussain AR, Sinaj AK, Manogaran PS, Al-Iomah NA, Maoqi A, Atizado V, Al-Dayer F, Belgauami A, El-Soh H, et al: Role of phosphatidylinositol 3-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2005, 108:4178-4186.

130. Daitoku H, Fukamizu A: FOXO transcription factors in the regulatory networks of longevity. J Biochem 2007, 141:769-774.

131. van der Heide LP, Smidt MP: Regulation of FoxO activity by CBP/p300-mediated acetylation. Trends Biochem Sci 2005, 30:81-86.

132. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, et al: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.

133. Imai S, Armstrong CM, Kaeberlein M, Guarente L: Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.

134. Shankar S, Ganapathy S, Hingorani SR, Srivastava RK: EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 2008, 13:440-452.

135. Shankar S, Siddiqui I, Srivastava RK: Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem 2007, 304:273-285.